Roche Diabets - Search News

Roche, Obesity and Drug Deal

NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide.

Financial Times · 1d

Roche signs biggest-ever obesity drug deal

Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma.

STAT · 1d

Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital increase.

Roche And Zealand Team Up To Develop Petrelintide

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

pharmaphorum10d

Roche app relieves diabetes distress in clinical trial

The new trial investigated the role of the Pro version of the mySugr app, a digital diabetes logbook which Roche acquired along with its developer in 2017 and – in a defining moment for digital ...

The Indianapolis Star11y

Roche to cut diabetes care jobs in Indianapolis, Fishers

Roche Diagnostics is cutting an unspecified number of jobs at two locations in Central Indiana as it struggles to cope with changing conditions in the diabetes care market. Company spokesman Todd ...

Nasdaq1mon

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

“Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a potentially blinding diabetic eye condition,” said Levi Garraway, MD, PhD, Roche's ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results